HK1138292A1 - Potent and selective mediators of cholesterol efflux - Google Patents

Potent and selective mediators of cholesterol efflux

Info

Publication number
HK1138292A1
HK1138292A1 HK10105040.7A HK10105040A HK1138292A1 HK 1138292 A1 HK1138292 A1 HK 1138292A1 HK 10105040 A HK10105040 A HK 10105040A HK 1138292 A1 HK1138292 A1 HK 1138292A1
Authority
HK
Hong Kong
Prior art keywords
cholesterol efflux
potent
polypeptides
apo
parallels
Prior art date
Application number
HK10105040.7A
Other languages
English (en)
Inventor
John K Bielicki
Jan Johansson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1138292A1 publication Critical patent/HK1138292A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK10105040.7A 2006-12-13 2010-05-24 Potent and selective mediators of cholesterol efflux HK1138292A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87490906P 2006-12-13 2006-12-13
PCT/US2007/087477 WO2008115303A2 (en) 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
HK1138292A1 true HK1138292A1 (en) 2010-08-20

Family

ID=39766652

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10105040.7A HK1138292A1 (en) 2006-12-13 2010-05-24 Potent and selective mediators of cholesterol efflux

Country Status (11)

Country Link
US (1) US8987192B2 (ru)
EP (1) EP2121746B1 (ru)
JP (1) JP2010513311A (ru)
CN (1) CN101675072A (ru)
AT (1) ATE533783T1 (ru)
AU (1) AU2007349237B2 (ru)
CA (1) CA2672131C (ru)
DK (1) DK2121746T3 (ru)
ES (1) ES2377329T3 (ru)
HK (1) HK1138292A1 (ru)
WO (1) WO2008115303A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010014003A (es) 2008-06-18 2011-02-15 Univ California Mediadores de peptido mejorados de eflujo de colesterol.
EP2517013A4 (en) * 2009-12-23 2013-07-17 Artery Therapeutics Inc DIAGNOSIS AND TREATMENT OF DISEASES ASSOCIATED WITH DEFICIENT REVERSE CHOLESTER INTRANSPORT
US20130123173A1 (en) * 2010-04-28 2013-05-16 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
SG11201507287SA (en) 2013-03-15 2015-10-29 Univ California Peptides having reduced toxicity that stimulate cholesterol efflux
US11091529B2 (en) * 2014-09-17 2021-08-17 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035163T2 (de) 1999-03-15 2008-02-21 University Of British Columbia, Vancouver Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
EP1274717B1 (en) * 2000-04-06 2008-02-27 Kos Pharmaceuticals, Inc. Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
EP1706131A4 (en) * 2003-12-15 2009-08-12 Univ California HELICOIDAL SYNTHETIC PEPTIDES STIMULATING THE EXTRACTION OF CHOLESTEROL FROM CELLS
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls

Also Published As

Publication number Publication date
WO2008115303A2 (en) 2008-09-25
AU2007349237B2 (en) 2014-01-23
US8987192B2 (en) 2015-03-24
US20120329703A1 (en) 2012-12-27
AU2007349237A1 (en) 2008-09-25
CA2672131C (en) 2016-06-07
CN101675072A (zh) 2010-03-17
CA2672131A1 (en) 2008-09-25
EP2121746B1 (en) 2011-11-16
ES2377329T3 (es) 2012-03-26
WO2008115303A3 (en) 2008-12-24
JP2010513311A (ja) 2010-04-30
DK2121746T3 (da) 2012-03-05
EP2121746A2 (en) 2009-11-25
ATE533783T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
WO2009155366A3 (en) Improved peptide mediators of cholesterol efflux
HK1138292A1 (en) Potent and selective mediators of cholesterol efflux
WO2007106721A3 (en) Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
WO2006045096A3 (en) Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200732296A (en) Novel compounds
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2005118511A3 (en) Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
WO2007131219A3 (en) Cannabinoid receptor antagonists/inverse agonists
WO2007044763A3 (en) System and method for detecting fraudulent transactions
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
WO2006020040A3 (en) Apolipoprotein a1 mimetics and uses thereof
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2007098113A3 (en) Ccr3 inhibition for ocular angiogenesis and macular degeneration
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2006076736A3 (en) Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
WO2006022955A3 (en) Topoisomerase inhibitors
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2007135571A3 (en) Blood group antigens of different types for diagnostic and therapeutic applications
WO2008134665A8 (en) Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
WO2011003100A3 (en) Compositions and methods for diagnosing and/or treating influenza infection
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181207